Retatrutide

Overview

Retatrutide (development code LY3437943, informally "Triple G") is a single-molecule agonist that activates three incretin and metabolic receptors at once: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and the glucagon receptor. It is being developed by Eli Lilly as a once-weekly subcutaneous injection for obesity and related cardiometabolic conditions.

It represents the next conceptual step beyond the dual GIP/GLP-1 agonist tirzepatide (Mounjaro/Zepbound): where tirzepatide hits two receptors, retatrutide adds glucagon-receptor activity, which appears to push weight loss into a new range.

Regulatory status (as of October 2026): Retatrutide is investigational and not approved by the FDA or any major regulator. Lilly has stated it plans to submit to the FDA in Q1 2027. No approval date exists yet; treat any specific approval timeline you see online as speculation. It also cannot be lawfully compounded, and the FDA has issued warning letters to sellers of unapproved retatrutide.

Mechanism

Each of the three receptor targets contributes a distinct effect, and the combination is the point:

• GLP-1 — suppresses appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion. This is the backbone shared by semaglutide and tirzepatide.
• GIP — complements GLP-1 with additional insulinotropic and appetite-modulating effects, and may improve tolerability of the GLP-1 component.
• Glucagon — the differentiator. Glucagon-receptor agonism increases energy expenditure and promotes hepatic fat oxidation. Historically, glucagon's tendency to raise blood glucose made it hard to use therapeutically; pairing it with potent GLP-1/GIP activity offsets that, so the net effect is increased calorie burn and improved glycemia.

The working hypothesis is that GLP-1 and GIP reduce energy intake while glucagon raises energy expenditure — attacking the energy-balance equation from both sides. The glucagon arm is also of particular interest for liver fat, which is reflected in the dedicated MASLD trial below.

Clinical Data

Phase 2 — NEJM 2023 (the foundational human trial)

The pivotal Phase 2 trial (Jastreboff AM, Kaplan LM, Frías JP, et al., New England Journal of Medicine, 2023; NCT04881760) randomized 338 adults with obesity to retatrutide (1, 4, 8, or 12 mg) or placebo:

• 24.2% mean body-weight reduction at the 12 mg dose over 48 weeks
• Clear dose-dependent response across all cohorts
• Improvements in fasting glucose, triglycerides, and blood pressure
• Mostly mild-to-moderate, dose-related gastrointestinal side effects

At the time, 24.2% was the highest weight-loss figure reported for any pharmacological agent in a trial of this kind.

Phase 3 — the TRIUMPH program

The Phase 3 registrational program is named TRIUMPH and comprises four trials (design and rationale published in Diabetes, Obesity & Metabolism, 2026):

| Trial | Population | Duration | Status (mid-2026) | |---|---|---|---| | TRIUMPH-1 | Obesity/overweight without type 2 diabetes (nested OSA and knee-OA sub-studies) | 80 weeks | Topline reported May 2026 | | TRIUMPH-2 | Obesity/overweight with type 2 diabetes | 80 weeks | Topline Jul 2026; published in The Lancet Sep 2026 | | TRIUMPH-3 | Class II/III obesity with established cardiovascular disease | 80 weeks | Topline reported Jul 2026 | | TRIUMPH-4 | Obesity/overweight with knee osteoarthritis | 68 weeks | Topline reported Dec 2025 |

TRIUMPH-4 topline (December 2025): In 445 participants with knee osteoarthritis, the 12 mg dose produced an average 28.7% body-weight reduction (≈32 kg) at 68 weeks, alongside substantial osteoarthritis pain relief (WOMAC pain reduced by up to ~75%), with more than 1 in 8 treated patients reporting complete freedom from knee pain at trial end.

TRIUMPH-1 topline (May 2026): In the pivotal obesity trial, 80-week weight loss was 19.0% (4 mg), 25.9% (9 mg), and 28.3% (12 mg) versus 2.2% for placebo. Roughly 45% of 12 mg patients lost ≥30% of their body weight. In an extended-follow-up subgroup (baseline BMI ≥35), weight loss reached up to 30.3% by 104 weeks.

TRIUMPH-2 (published in The Lancet, September 2026): In 1,152 adults with obesity and type 2 diabetes, 80-week weight loss was 12.7% (4 mg), 19.1% (9 mg), and 20.8% (12 mg) versus 4.0% for placebo, with A1C reductions of up to 1.6 points and up to 40% of participants reaching a normal A1C (<5.7%). Discontinuation due to adverse events was 3.8–11.6% across doses versus 4.9% for placebo, and dysesthesia (altered skin sensation) occurred in 4.5–7.3% of retatrutide groups.

TRIUMPH-3 topline (July 2026): In adults with severe obesity and established cardiovascular disease, weight loss reached up to 22.6% at 80 weeks. Cardiovascular events occurred less often than anticipated in both arms, so the trial cannot settle cardiovascular safety either way: 44 vs 52 MACE-5 events (HR 0.82, 95% CI 0.55–1.22), but 27 vs 23 MACE-3 events (HR 1.12, 95% CI 0.64–1.96) — neither difference is statistically meaningful. A separate dedicated outcomes trial, TRIUMPH-Outcomes (NCT06383390), is registered.

Important caveat: TRIUMPH-2 is the only Phase 3 trial published in full. TRIUMPH-1, -3, and -4 figures are topline results from Lilly press releases, and final peer-reviewed numbers can differ.

Liver fat — Phase 2a MASLD trial (Nature Medicine 2024)

A dedicated Phase 2a trial in metabolic dysfunction-associated steatotic liver disease (MASLD/NAFLD), published in Nature Medicine (2024), reported large reductions in liver fat content with retatrutide — consistent with the glucagon component's role in hepatic fat oxidation. This positions retatrutide as a candidate not just for weight loss but for fatty-liver disease.

How It Compares

| Agent | Receptors | Reported peak trial weight loss | |---|---|---| | Semaglutide (Wegovy) | GLP-1 | ~15% (STEP 1, 68 wk) | | Tirzepatide (Zepbound) | GIP + GLP-1 | ~21–23% (SURMOUNT-1, 72 wk) | | Retatrutide (investigational) | GIP + GLP-1 + glucagon | ~28–30% (TRIUMPH topline) |

The trend across these molecules is clear: adding receptor targets has, so far, increased the ceiling on weight loss. Retatrutide's glucagon arm is the current frontier.

Research Notes & Cautions

• All human efficacy data are industry-sponsored (Eli Lilly). There is no independent confirmation outside Lilly's clinical program.
• The glucagon component warrants monitoring — transient heart-rate increases are reported, and TRIUMPH-3 had too few cardiovascular events to answer the long-term safety question, which a dedicated outcomes trial (TRIUMPH-Outcomes) is meant to address.
• Trial dosing uses a slow, structured escalation (starting at low milligram doses and titrating upward over months) specifically to manage gastrointestinal tolerability. Community protocols that escalate faster are extrapolations and carry meaningful risk of nausea, vomiting, and dehydration.
• Because retatrutide is investigational, any non-trial material is, by definition, not pharmaceutical-grade and not quality-controlled.

Bottom Line

Retatrutide is the most closely watched compound in the obesity space heading into a likely regulatory filing. The Phase 2 result (24.2%) has been reinforced by Phase 3 topline figures approaching 28–30%, with added signals in osteoarthritis pain and liver fat. TRIUMPH-2 has now been published in full (20.8% in type 2 diabetes), and Lilly plans an FDA submission in Q1 2027. The open questions as of October 2026: full publication of the other Phase 3 trials, long-term cardiovascular safety (TRIUMPH-3 was inconclusive on events), and the eventual FDA review.